In the long human struggle to make medicine easier to bear, a South Korean company has quietly crossed a threshold that many believed unreachable: a skin patch delivering a major obesity drug with the same potency as an injection, but without the needle, the cold chain, or the daily ritual of compliance. Announced in August 2025, Daewoong Therapeutics' semaglutide microneedle patch achieved over 80 percent bioavailability in human trials — a figure that reframes what painless drug delivery can mean for millions of patients worldwide. The achievement arrives as the global obesity treatment mark
Daewoong's Semaglutide Patch Achieves 80% Bioavailability, Setting New Obesity Treatment Standard
The first to overcome the high-dose barrier that had limited microneedle technology for years.
Mark
Why does the delivery method matter so much? Semaglutide works the same way whether it's injected or patched.
Mimi
The drug works the same, yes. But how people actually use it is everything. A patient who dreads needles might skip doses or stop treatment entirely. A patch removes that friction. And the oral version requires fasting and water restrictions—real barriers for people managing other chronic conditions.
Mark
So this is about adherence, not efficacy.
Mimi
Exactly. The drug itself is proven. What's unsolved is getting people to stay on it long-term. That's where the market leaders will emerge.
Mark
The 80 percent bioavailability figure—how significant is that really?
Mimi
It's the difference between a patch that's a novelty and one that's a genuine alternative to injections. At 30 percent, you'd need a much larger patch or more frequent dosing. At 80 percent, you can match the injectable schedule with something painless.
Mark
Room-temperature stability seems like a small detail.
Mimi
It's not small in practice. Cold-chain logistics are expensive and fragile, especially in developing countries. A patch that works at room temperature opens markets that injectable semaglutide can't easily reach.
Mark
What's the risk here? Why hasn't someone done this before?
Mimi
The engineering is genuinely hard. You have to dissolve microneedles precisely, load enough drug without degrading it, and ensure uniform distribution across thousands of tiny needles. Most attempts failed at the high-dose step. Daewoong cracked it, but that doesn't guarantee regulatory approval or that patients will prefer it to injections they already know work.
Le Pouls
- A once-dismissed frontier in drug delivery has suddenly become urgent: Daewoong's microneedle patch matched injectable semaglutide's potency at over 80% bioavailability, shattering the ~30% ceiling that had long stalled the field.
- The tension is practical as much as scientific — weekly injections cause pain, oral tablets demand fasting and precise timing, and both drive patients to abandon treatment in a market where adherence is everything.
- The patch's room-temperature stability disrupts another chokepoint: injectable semaglutide requires refrigeration, limiting access in regions without reliable cold chains and inflating distribution costs globally.
- Daewoong's CLOPAM platform — backed by 52 worldwide patents — is now being positioned not as a single product but as a licensing engine, with the company seeking global partners to carry the technology across multiple biologic drugs.
- The trajectory points toward a reshaping of injectable medicine broadly, with regulatory approval the remaining gate between this laboratory breakthrough and the patients who could benefit from it.
In the long human struggle to make medicine easier to bear, a South Korean company has quietly crossed a threshold that many believed unreachable: a skin patch delivering a major obesity drug with the same potency as an injection, but without the needle, the cold chain, or the daily ritual of compliance. Announced in August 2025, Daewoong Therapeutics' semaglutide microneedle patch achieved over 80 percent bioavailability in human trials — a figure that reframes what painless drug delivery can mean for millions of patients worldwide. The achievement arrives as the global obesity treatment market races toward a projected $60.5 billion by 2030, where the winners will likely be those who solve not just the science, but the lived experience of taking medicine week after week.
A South Korean pharmaceutical company has cleared a barrier that had long frustrated drug delivery researchers: engineering a skin patch for semaglutide — the blockbuster obesity drug — that delivers more than 80 percent of its dose into the bloodstream, matching the performance of a standard injection. Daewoong Pharmaceutical and its subsidiary Daewoong Therapeutics announced the results in August 2025, following a study of 70 healthy volunteers who received either the microneedle patch or a conventional subcutaneous injection. The comparison was striking. Existing microneedle patches achieve roughly 30 percent bioavailability. The oral tablet form of semaglutide delivers approximately 160 times less drug than the patch. And unlike the pill, which requires fasting, water restrictions, and careful timing, the patch needs only to be applied once a week.
The obesity drug market provides the backdrop for why this matters so urgently. Global sales reached $15.9 billion in 2024 and are forecast to hit $60.5 billion by 2030, driven largely by GLP-1 medications like semaglutide. But growth alone does not guarantee success — industry observers increasingly believe the companies that prevail will be those that make treatment easier to sustain. Injections are painful. Oral regimens are demanding. A weekly patch that requires no needle and no refrigeration addresses both problems at once, while also reducing the medical waste generated by syringes.
The technology, called CLOPAM, uses dissolving microneedles that carry a full therapeutic dose of semaglutide directly into skin tissue. Daewoong's leadership described the high-dose loading problem as the central obstacle that had defeated earlier attempts — previous patches simply could not carry enough drug to produce a meaningful clinical effect. The company says it solved this through pressurized drying and hermetic packaging that ensures uniform drug distribution and room-temperature stability.
With 52 patents filed globally, Daewoong is now pursuing licensing agreements and development partnerships, positioning CLOPAM as a platform for other biologic drugs beyond semaglutide. Regulatory approval remains the critical next step, but if the patch reaches patients, its implications may extend well beyond obesity — offering a new model for how injectable medications of many kinds are delivered.
A South Korean pharmaceutical company has engineered a semaglutide patch that delivers the obesity drug through the skin with remarkable efficiency—more than 80 percent of the dose reaching the bloodstream, compared to the injectable version. The achievement, announced in August 2025 by Daewoong Pharmaceutical and its subsidiary Daewoong Therapeutics, represents a significant leap in how obesity medications might be administered in the years ahead.
The study involved 70 healthy volunteers who received either a single microneedle patch or a standard subcutaneous injection of semaglutide. Researchers measured plasma concentrations and adjusted for equivalent dosing. The patch performed far better than any microneedle delivery system tested before. Existing patches of this type achieve only about 30 percent bioavailability. The oral tablet version of semaglutide, already on the market, delivers roughly 160 times less drug to the body than the patch does. The patch maintained therapeutic levels for a full week, suggesting that patients could apply it once weekly rather than enduring weekly injections or managing the complicated daily regimen required by the pill—which demands fasting, water restrictions, and careful timing around other medications.
The obesity treatment market is expanding rapidly. Global sales were valued at 15.9 billion dollars in 2024 and are projected to reach 60.5 billion by 2030. Most of that growth is driven by GLP-1 drugs like semaglutide, which suppress appetite and help regulate blood sugar. But the market is crowded, and experts believe the companies that win will be those that solve the practical problems patients face. Injections hurt. Pills require complicated adherence protocols that many people abandon. A patch that works as well as an injection but requires no needle, no cold storage, and only weekly application could reshape how millions of people manage their weight.
The technology behind the patch is called CLOPAM, a dissolving microneedle platform developed by Daewoong Therapeutics. The microneedles are made to dissolve into the skin, delivering the drug directly into tissue. The company uses pressurized drying and hermetic packaging to ensure uniform drug distribution and stability. The patch remains stable at room temperature, unlike injectable semaglutide, which must be refrigerated. This matters for distribution costs and for patients in regions without reliable cold chains. The patch also eliminates the medical waste generated by syringes and needles, a secondary benefit that aligns with healthcare sustainability goals.
Bok-Ki Kang, CEO of Daewoong Therapeutics, emphasized that the real challenge in microneedle delivery has always been fitting enough drug into a patch to produce a therapeutic effect. Previous attempts failed because they couldn't load a high enough dose. His team solved that problem, he said, by incorporating a full therapeutic dose of semaglutide into a single patch. Seong-Soo Park, co-CEO of Daewoong Pharmaceutical, called the work the first to overcome the high-dose barrier that had limited microneedle technology for years.
The company has filed 52 patents worldwide for the CLOPAM platform and is now pursuing global partnerships. Daewoong plans to license the technology, collaborate with other drugmakers on development, and eventually out-license it for commercialization. The company also intends to apply the microneedle platform to other biologic drugs beyond semaglutide, positioning itself as a provider of delivery technology rather than just a single-drug manufacturer. If the patch moves through regulatory approval and reaches patients, it could reshape not only how obesity is treated but also how other injectable medications are administered.
Citations marquantes
The microneedle patch must achieve not only high bioavailability but also a drug load sufficient for therapeutic effect. In this study, we incorporated a high dose of semaglutide into a single patch and showed the potential for once-weekly application.— Bok-Ki Kang, CEO of Daewoong Therapeutics
Microneedle formats have long promised better adherence, but high-dose delivery has been a challenge. This work is the first to overcome that barrier.— Seong-Soo Park, Co-CEO of Daewoong Pharmaceutical
Envie de l'histoire complète ?
Lire l'original sur The Manila Times ↗
Health & Medicine